Position Statement on Antiplatelet Therapy for East Asians With Coronary Artery Disease: 2025 Update. [PDF]
Gong Y +19 more
europepmc +1 more source
In the phase I/IIa GOING trial, an add‐on strategy with regorafenib followed by nivolumab showed a manageable safety profile and meaningful clinical activity in second‐line hepatocellular carcinoma, with a median overall survival of 25 months and 45% three‐year survival in sorafenib‐experienced patients.
Marco Sanduzzi‐Zamparelli +24 more
wiley +1 more source
Regression of a Cardiac Calcified Amorphous Tumor Under Antiplatelet Therapy in a Patient With Ischemic Stroke: A Case Report and Literature Review. [PDF]
Matsueda S +6 more
europepmc +1 more source
Agam Bansal +5 more
doaj +1 more source
Clinical Outcomes of Tegoprazan Versus Proton Pump Inhibitors in Patients Receiving Antiplatelet Therapy After Percutaneous Coronary Intervention: A Retrospective, Observational Study. [PDF]
Lee J +7 more
europepmc +1 more source
Inflammatory Markers and Stroke Outcomes: Lessons From Neutrophil Counts and Antiplatelet Therapy. [PDF]
Weiss A, Ding Y.
europepmc +1 more source
Effect of Extended Dual Antiplatelet Therapy on the Prognosis of Patients With ST Segment Elevation Myocardial Infarction Undergoing Percutaneous Coronary Intervention: A Retrospective Cohort Study. [PDF]
Li YC +7 more
europepmc +1 more source
Retinal Vascular Occlusion in Patients on Anticoagulation and Antiplatelet Therapy: a Case Report and Comprehensive Review. [PDF]
Madi M +7 more
europepmc +1 more source
Esophageal embolization for hemostasis in cancer patients presenting with upper gastrointestinal bleeding in the setting of antiplatelet therapy: A case report. [PDF]
Anh NT +7 more
europepmc +1 more source

